Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X to Present at the Small Cap Growth Virtual Investor Conference June 4th1.6.2026 15:30:00 CEST | Press release
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com CALGARY, AB / ACCESS Newswire / June 1, 2026 / Karbon-X Corp. (OTCQB:KARX), based in Calgary, Alberta focused on global carbon markets and climate infrastructure solutions, today announced that Chad Clovis, Chief Executive Officer will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on June 4, 2026 DATE: June 4th TIME: 10:00 AM ET REGISTER HERE Available for 1x1 meetings: June 5th-9th Schedule 1x1 Meetings here. This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive
Resin Solutions LLC Introduces "Stratix(TM)" Brand Architecture for Products Serving the Aerospace and Defense Applications1.6.2026 15:00:00 CEST | Press release
EXTON, PA / ACCESS Newswire / June 1, 2026 / Resin Solutions LLC, a leading provider of advanced material solutions, today announced the launch of Stratix™, a new brand identity reflecting the company's deepened strategic focus on the Aerospace and Defense sector. This new designation underscores the company's long-term commitment to supporting the unique and demanding requirements of aerospace and defense customers. By clearly bringing both its existing and in-development aerospace and defense products under the Stratix™ brand name, Resin Solutions aims enhance customer confidence, streamline product selection, and further strengthen its partnerships within the sector. The Stratix™ brand trademark will be applied to a growing portfolio of materials engineered to meet the rigorous performance, quality, and reliability expectations critical to aerospace and defense applications. Among the first products to carry the designation are Resin Solutions' flagship and highly-specified aerospac
AccessPay Appoints Johan Jardevall as CEO to Lead Next Phase of Growth1.6.2026 10:00:00 CEST | Press release
-- MANCHESTER, GB / ACCESS Newswire / June 1, 2026 / AccessPay, the leading bank integration provider, today announced the appointment of Johan Jardevall as Chief Executive Officer. Johan succeeds Anish Kapoor, who will become Chairman. Anish is stepping down after more than a decade leading the company through a significant period of growth, technology transformation, and platform development. Johan brings more than 25 years of experience leading and scaling enterprise software and SaaS businesses across Europe and the UK. He has held several senior executive and CEO positions within high-growth technology companies, with expertise spanning operational leadership, customer delivery, strategic growth, and product commercialisation. Most recently, Johan served as CEO of Person Centred Software, where he led the company through a significant phase of operational and commercial growth. The leadership transition follows AccessPay's recent strategic majority investment from Accel-KKR and ma
POLARIS Laboratories Joins the Dow Coolant Care Network as Testing Provider for DOWFROST Heat Transfer Fluids28.5.2026 15:00:00 CEST | Press release
INDIANAPOLIS, IN / ACCESS Newswire / May 28, 2026 / POLARIS Laboratories® today announced Dow has selected POLARIS Laboratories® as a testing provider for DOWFROST™ LC and HD Heat Transfer Fluids used in advanced cooling systems. This collaboration reinforces Dow's commitment to helping customers move beyond reactive maintenance practices toward proactive, data-driven fluid management. DOWFROST™ Heat Transfer Fluids are engineered to support next-generation data center cooling, including direct-to-chip liquid cooling architectures. Formulated with high-purity propylene glycol and advanced inhibitor technology, these fluids enable efficient heat removal, corrosion protection, and long-term operational stability in high-performance computing environments. To meet thermal demands from Artificial Intelligence (AI) and high-density computing, monitoring liquid cooling fluid is critical to protect uptime, maintain performance and reduce operational risk. The Dow Coolant Care Network integrat
Caldwell Strengthens Financial Services and Fintech Capabilities with Addition of Alex Langridge in London28.5.2026 10:30:00 CEST | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / May 28, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Alex Langridge as a Partner in the firm's Financial Services Practice. Based in London, Langridge advises clients across financial services and fintech on senior executive and board appointments, succession planning, organizational design, and transformational leadership hiring. Based in London, Alex Langridge joins Caldwell's Financial Services Practice, bringing deep expertise across banking, fintech, insurance, and transformational leadership advisory. Langridge brings more than 20 years of executive search and leadership advisory experience, partnering with banks, insurers, fintechs, and private equity- and venture-backed businesses across the UK and EMEA. He is particularly known for placing P&L, operations, commercial, product, technology, and digital leaders into high-impact transformational roles, as well as for helping cli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom